LIXA is focused on developing scalable antibiofilm technologies to treat antimicrobial resistance (AMR), for anyone, anything and anywhere. Our technologies disrupt both mature and immature biofilms and are compatible with most existing antimicrobials. We are open to partnerships to develop real solutions to AMR.
Ecosystem activity
2025
1 milestone
January
Joined
2022
1 milestone
December
Won Wesfarmers Wellbeing Platinum Award from
2020
1 milestone
December
Received $40K grant from
Government of Western Australia
Is this your organisation?
Claim this profile to add your story, team and milestones.